{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:30:24Z","timestamp":1790202624604,"version":"4.1.0"},"reference-count":52,"publisher":"Japan Atherosclerosis Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2020,6,1]]},"DOI":"10.5551\/jat.rv17040","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T22:05:19Z","timestamp":1588197919000},"page":"489-498","source":"Crossref","is-referenced-by-count":24,"title":["Low-Density Lipoprotein Cholesterol Level cannot be too Low: Considerations from Clinical Trials, Human Genetics, and Biology"],"prefix":"10.5551","volume":"27","author":[{"given":"Hayato","family":"Tada","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Usui","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Sakata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Takamura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masa-aki","family":"Kawashiri","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Wissler RW. Update on the pathogenesis of atherosclerosis. Am J Med, 1991; 91: 3S-9S","DOI":"10.1016\/0002-9343(91)90050-8"},{"key":"2","unstructured":"2) Friedman M. Pathogenesis of the spontaneous atherosclerotic plaque. A study on the A\/Friedman M: Pathogenesis of the spontaneous atherosclerotic plaque. A study on the cholesterol-fed rabbit. Arch Pathol, 1963; 76: 318-329"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med, 1971; 74: 1-12","DOI":"10.7326\/0003-4819-74-1-1"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Mabuchi H. Half a Century Tales of Familial Hypercholesterolemia (FH) in Japan. J Atheroscler Thromb, 2017; 24: 189-207","DOI":"10.5551\/jat.RV16008"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Peloso GM, Nomura A, Khera AV, Chaffin M, Won HH, Ardissino D, Danesh J, Schunkert H, Wilson JG, Samani N, Erdmann J, McPherson R, Watkins H, Saleheen D, McCarthy S, Teslovich TM, Leader JB, Lester Kirchner H, Marrugat J, Nohara A, Kawashiri MA, Tada H, Dewey FE, Carey DJ, Baras A, Kathiresan S. Rare Protein-Truncating Variants in APOB, Lower Low-Density Lipoprotein Cholesterol, and Protection Against Coronary Heart Disease. Circ Genom Precis Med, 2019; 12: e002376","DOI":"10.1161\/CIRCGEN.118.002376"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Cholesterol Treatment Trialists' (CTT) Collaboration1, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 2010; 376: 1670-1681","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med, 2015; 372: 2387-2397","DOI":"10.1056\/NEJMoa1410489"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med, 2017; 376: 1713-1722","DOI":"10.1056\/NEJMoa1615664"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med, 2018; 379: 2097-2107","DOI":"10.1056\/NEJMoa1801174"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, Umemoto S, Egusa G, Ohmura H, Okamura T, Kihara S, Koba S, Saito I, Shoji T, Daida H, Tsukamoto K, Deguchi J, Dohi S, Dobashi K, Hamaguchi H, Hara M, Hiro T, Biro S, Fujioka Y, Maruyama C, Miyamoto Y, Murakami Y, Yokode M, Yoshida H, Rakugi H, Wakatsuki A, Yamashita S; Committee for Epidemiology and Clinical Management of Atherosclerosis. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. J Atheroscler Thromb, 2018; 25: 846-984","DOI":"10.5551\/jat.GL2017"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J, 2020; 41: 111-188","DOI":"10.1093\/eurheartj\/ehz455"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Tada H, Kawashiri MA, Nohara A, Inazu A, Kobayashi J, Yasuda K, Mabuchi H, Yamagishi M, Hayashi K. Lipid Management in a Japanese Community: Attainment Rate of Target Set by the Japan Atherosclerosis Society Guidelines for the Prevention of Atherosclerotic Cardiovascular Diseases 2012. J Atheroscler Thromb, 2017; 24: 338-345","DOI":"10.5551\/jat.36004"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Makino H, Koezuka R, Tamanaha T, Ogura M, Matsuki K, Hosoda K, Harada-Shiba M. Familial Hypercholesterolemia and Lipoprotein Apheresis. J Atheroscler Thromb, 2019; 26: 679-687","DOI":"10.5551\/jat.RV17033"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Tada H, Kawashiri MA, Ikewaki K, et al. Altered metabolism of low-density lipoprotein and very-low-density lipoprotein remnant in autosomal recessive hypercholesterolemia: results from stable isotope kinetic study in vivo. Circ Cardiovasc Genet, 2012; 5: 35-41","DOI":"10.1161\/CIRCGENETICS.111.960948"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Tada H, Nohara A, Inazu A, et al. Sitosterolemia, Hypercholesterolemia, and Coronary Artery Disease. J Atheroscler Thromb, 2018; 25: 783-789","DOI":"10.5551\/jat.RV17024"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Tada H, Kawashiri MA, Yamagishi M. Clinical Perspectives of Genetic Analyses on Dyslipidemia and Coronary Artery Disease. J Atheroscler Thromb, 2017; 24: 452-461","DOI":"10.5551\/jat.RV17002"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Yang XP, Inazu A, Yagi K, Kajinami K, Koizumi J, Mabuchi H. Abetalipoproteinemia caused by maternal isodisomy of chromosome 4q containing an intron 9 splice acceptor mutation in the microsomal triglyceride transfer protein gene. Arterioscler Thromb Vasc Biol, 1999; 19: 1950-1955","DOI":"10.1161\/01.ATV.19.8.1950"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Kawashiri MA, Tada H, Hashimoto M, Taniyama M, Nakano T, Nakajima K, Inoue T, Mori M, Nakanishi C, Konno T, Hayashi K, Nohara A, Inazu A, Koizumi J, Ishihara H, Kobayashi J, Hirano T, Mabuchi H, Yamagishi M. Extreme Contrast of Postprandial Remnant-Like Particles Formed in Abetalipoproteinemia and Homozygous Familial Hypobetalipoproteinemia. JIMD Rep, 2015; 22: 85-94","DOI":"10.1007\/8904_2015_415"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Tada H, Okada H, Nomura A, Nohara A, Takamura M, Kawashiri MA. A Healthy Family of Familial Hypobetalipoproteinemia Caused by a Protein-truncating Variant in the PCSK9 Gene. Intern Med, 2020 in press","DOI":"10.2169\/internalmedicine.3737-19"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Myocardial Infarction Genetics Consortium Investigators, Stitziel NO, Won HH, Morrison AC, Peloso GM, Do R, Lange LA, Fontanillas P, Gupta N, Duga S, Goel A, Farrall M, Saleheen D, Ferrario P, K\u00f6nig I, Asselta R, Merlini PA, Marziliano N, Notarangelo MF, Schick U, Auer P, Assimes TL, Reilly M, Wilensky R, Rader DJ, Hovingh GK, Meitinger T, Kessler T, Kastrati A, Laugwitz KL, Siscovick D, Rotter JI, Hazen SL, Tracy R, Cresci S, Spertus J, Jackson R, Schwartz SM, Natarajan P, Crosby J, Muzny D, Ballantyne C, Rich SS, O'Donnell CJ, Abecasis G, Sunaev S, Nickerson DA, Buring JE, Ridker PM, Chasman DI, Austin E, Kullo IJ, Weeke PE, Shaffer CM, Bastarache LA, Denny JC, Roden DM, Palmer C, Deloukas P, Lin DY, Tang ZZ, Erdmann J, Schunkert H, Danesh J, Marrugat J, Elosua R, Ardissino D, McPherson R, Watkins H, Reiner AP, Wilson JG, Altshuler D, Gibbs RA, Lander ES, Boerwinkle E, Gabriel S, Kathiresan S. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med, 2014; 371: 2072-2082","DOI":"10.1056\/NEJMoa1405386"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Ference BA, Ray KK, Catapano AL, Ference TB, Burgess S, Neff DR, Oliver-Williams C, Wood AM, Butterworth AS, Di Angelantonio E, Danesh J, Kastelein JJP, Nicholls SJ. Mendelian Randomization Study of ACLY and Cardiovascular Disease. N Engl J Med, 2019; 380: 1033-1042","DOI":"10.1056\/NEJMoa1806747"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Stitziel NO, Khera AV, Wang X, Bierhals AJ, Vourakis AC, Sperry AE, Natarajan P, Klarin D, Emdin CA, Zekavat SM, Nomura A, Erdmann J, Schunkert H, Samani NJ, Kraus WE, Shah SH, Yu B, Boerwinkle E, Rader DJ, Gupta N, Frossard PM, Rasheed A, Danesh J, Lander ES, Gabriel S, Saleheen D, Musunuru K, Kathiresan S; PROMIS and Myocardial Infarction Genetics Consortium Investigators. ANGPTL3 Deficiency and Protection Against Coronary Artery Disease. J Am Coll Cardiol, 2017; 69: 2054-2063","DOI":"10.1016\/j.jacc.2017.02.030"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Benn M, Nordestgaard BG, Grande P, Schnohr P, Tybjaerg-Hansen A. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol, 2010; 55: 2833-2842","DOI":"10.1016\/j.jacc.2010.02.044"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Nomura A, Emdin CA, Won HH, Peloso G, Natarajan P, Ardissino D, Danesh J, Schunkert H, Correa A, Bown M, Samani N, Erdmann J, McPherson R, Watkins H, Saleheen D, Elosua R, Kawashiri MA, Tada H, Gupta N, Shah S, Rader DJ, Gabriel S, Khera AV, Kathiresan S. Heterozygous ATP-binding Cassette Transporter G5 Gene Deficiency and Risk of Coronary Artery Disease. Circ Genom Precis Med, 2020 in press","DOI":"10.1101\/780734"},{"key":"25","doi-asserted-by":"crossref","unstructured":"26) Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen\/progestin Replacement Study (HERS) Research Group. JAMA, 1998; 280: 605-613","DOI":"10.1001\/jama.280.7.605"},{"key":"26","doi-asserted-by":"crossref","unstructured":"27) AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med, 2011; 365: 2255-2267","DOI":"10.1056\/NEJMoa1107579"},{"key":"27","doi-asserted-by":"crossref","unstructured":"28) Forrest MJ, Bloomfield D, Briscoe RJ, Brown PN, Cumiskey AM, Ehrhart J, Hershey JC, Keller WJ, Ma X, McPherson HE, Messina E, Peterson LB, Sharif-Rodriguez W, Siegl PK, Sinclair PJ, Sparrow CP, Stevenson AS, Sun SY, Tsai C, Vargas H, Walker M 3rd, West SH, White V, Woltmann RF. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol, 2008; 154: 1465-1473","DOI":"10.1038\/bjp.2008.229"},{"key":"28","doi-asserted-by":"crossref","unstructured":"29) Itoh H, Komuro I, Takeuchi M, Akasaka T, Daida H, Egashira Y, Fujita H, Higaki J, Hirata KI, Ishibashi S, Isshiki T, Ito S, Kashiwagi A, Kato S, Kitagawa K, Kitakaze M, Kitazono T, Kurabayashi M, Miyauchi K, Murakami T, Murohara T, Node K, Ogawa S, Saito Y, Seino Y, Shigeeda T, Shindo S, Sugawara M, Sugiyama S, Terauchi Y, Tsutsui H, Ueshima K, Utsunomiya K, Yamagishi M, Yamazaki T, Yo S, Yokote K, Yoshida K, Yoshimura M, Yoshimura N, Nakao K, Nagai R; EMPATHY Investigators. Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study. Diabetes Care, 2018; 41: 1275-1284","DOI":"10.2337\/dc17-2224"},{"key":"29","doi-asserted-by":"crossref","unstructured":"30) Taguchi I, Iimuro S, Iwata H, Takashima H, Abe M, Amiya E, Ogawa T, Ozaki Y, Sakuma I, Nakagawa Y, Hibi K, Hiro T, Fukumoto Y, Hokimoto S, Miyauchi K, Yamazaki T, Ito H, Otsuji Y, Kimura K, Takahashi J, Hirayama A, Yokoi H, Kitagawa K, Urabe T, Okada Y, Terayama Y, Toyoda K, Nagao T, Matsumoto M, Ohashi Y, Kaneko T, Fujita R, Ohtsu H, Ogawa H, Daida H, Shimokawa H, Saito Y, Kimura T, Inoue T, Matsuzaki M, Nagai R. High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial. Circulation, 2018; 137: 1997-2009","DOI":"10.1161\/CIRCULATIONAHA.117.032615"},{"key":"30","doi-asserted-by":"crossref","unstructured":"31) HPS3\/TIMI55\u2013REVEAL Collaborative Group, Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E, Sammons E, Landray MJ. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med, 2017; 377: 1217-1227","DOI":"10.1056\/NEJMoa1706444"},{"key":"31","doi-asserted-by":"crossref","unstructured":"32) Steg PG, Szarek M, Bhatt DL, Bittner VA, Br\u00e9geault MF, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Ostadal P, Parkhomenko A, Pordy R, Roe MT, Tricoci P, Vogel R, White HD, Zeiher AM, Schwartz GG. Effect of Alirocumab on Mortality After Acute Coronary Syndromes. Circulation, 2019; 140: 103-112","DOI":"10.1161\/CIRCULATIONAHA.118.038840"},{"key":"32","doi-asserted-by":"crossref","unstructured":"33) Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Ott BR, Kanevsky E, Pineda AL, Somaratne R, Wasserman SM, Keech AC, Sever PS, Sabatine MS; FOURIER Investigators. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet, 2017; 390: 1962-1971","DOI":"10.1016\/S0140-6736(17)32290-0"},{"key":"33","doi-asserted-by":"crossref","unstructured":"34) Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science, 1986; 232: 34-47","DOI":"10.1126\/science.3513311"},{"key":"34","doi-asserted-by":"crossref","unstructured":"35) Takenaka A, Matsumoto Y, Nagaya A, Watanabe K, Goto S, Suryobroto B, Takenaka O. Plasma cholesterol levels in free-ranging macaques compared with captive macaques and humans. Primates, 2000; 41: 299-309","DOI":"10.1007\/BF02557599"},{"key":"35","unstructured":"36) Fedigan, L., 1991. Lifespan and reproduction in Japanese macaque females. In: The Monkeys of Arashiyama: 35 Years of Research in Japan and the West, L. M. Fedigan & P. J. Asquith (eds.), State Univ. of New York Press, Albany, New York, pp. 140-154"},{"key":"36","doi-asserted-by":"crossref","unstructured":"37) Benn M, Nordestgaard BG, Frikke-Schmidt R, Tybj\u00e6rg-Hansen A. Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study. BMJ, 2017; 357: j1648","DOI":"10.1136\/bmj.j1648"},{"key":"37","doi-asserted-by":"crossref","unstructured":"38) Sun L, Clarke R, Bennett D, Guo Y, Walters RG, Hill M, Parish S, Millwood IY, Bian Z, Chen Y, Yu C, Lv J, Collins R, Chen J, Peto R, Li L, Chen Z; China Kadoorie Biobank Collaborative Group; International Steering Committee; International Co-ordinating Centre, Oxford; National Co-ordinating Centre, Beijing; Regional Co-ordinating Centres. Causal associations of blood lipids with risk of ischemic stroke and intracerebral hemorrhage in Chinese adults. Nat Med, 2019; 25: 569-574","DOI":"10.1038\/s41591-019-0366-x"},{"key":"38","doi-asserted-by":"crossref","unstructured":"39) Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbal\u00e1n R, \u0160pinar J, Park JG, White JA, Bohula EA, Braunwald E; IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation, 2018; 137: 1571-1582","DOI":"10.1161\/CIRCULATIONAHA.117.030950"},{"key":"39","doi-asserted-by":"crossref","unstructured":"40) Yamaguchi J, Kawada-Watanabe E, Koyanagi R, Arashi H, Sekiguchi H, Nakao K, Tobaru T, Tanaka H, Oka T, Endo Y, Saito K, Uchida T, Matsui K, Ogawa H, Hagiwara N. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub-analysis of HIJ-PROPER. Atherosclerosis, 2018; 274: 139-145","DOI":"10.1016\/j.atherosclerosis.2018.04.036"},{"key":"40","doi-asserted-by":"crossref","unstructured":"41) Tada H, Okada H, Nomura A, Takamura M, Kawashiri MA. Beneficial effect of ezetimibe-atorvastatin combination therapy in patients with a mutation in ABCG5 or ABCG8 gene. Lipids Health Dis, 2020; 19: 3","DOI":"10.1186\/s12944-019-1183-4"},{"key":"41","doi-asserted-by":"crossref","unstructured":"42) Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen TR, Sabatine MS. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation, 2018; 137: 338-350","DOI":"10.1161\/CIRCULATIONAHA.117.032235"},{"key":"42","doi-asserted-by":"crossref","unstructured":"43) Shapiro MD, Minnier J, Tavori H, Kassahun H, Flower A, Somaratne R, Fazio S. Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab. J Am Heart Assoc, 2019; 8 :e010932","DOI":"10.1161\/JAHA.118.010932"},{"key":"43","doi-asserted-by":"crossref","unstructured":"44) Damask A, Steg PG, Schwartz GG, Szarek M, Hagstr\u00f6m E, Badimon L, Chapman MJ, Boileau C, Tsimikas S, Ginsberg HN, Banerjee P, Manvelian G, Pordy R, Hess S, Overton JD, Lotta LA, Yancopoulos GD, Abecasis GR, Baras A, Paulding C; Regeneron Genetics Center and the ODYSSEY OUTCOMES Investigators. Patients with High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit from Alirocumab Treatment in the Odyssey Outcomes Trial. Circulation, 2020; 141: 624-636","DOI":"10.1161\/CIRCULATIONAHA.119.044434"},{"key":"44","doi-asserted-by":"crossref","unstructured":"45) Marston NA, Kamanu FK, Nordio F, Gurmu Y, Roselli C, Sever PS, Pedersen TR, Keech AC, Wang H, Lira Pineda A, Giugliano RP, Lubitz SA, Ellinor PT, Sabatine MS, Ruff CT. Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial. Circulation, 2020; 141: 616-623","DOI":"10.1161\/CIRCULATIONAHA.119.043805"},{"key":"45","doi-asserted-by":"crossref","unstructured":"46) Luirink IK, Wiegman A, Kusters DM, Hof MH, Groothoff JW, de Groot E, Kastelein JJP, Hutten BA. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. N Engl J Med, 2019; 381: 1547-1556","DOI":"10.1056\/NEJMoa1816454"},{"key":"46","doi-asserted-by":"crossref","unstructured":"47) Brandts J, Ray KK. LDL-Cholesterol Lowering Strategies and Population Health - Time to Move to a Cumulative Exposure Model. Circulation, 2020 in press","DOI":"10.1161\/CIRCULATIONAHA.119.043406"},{"key":"47","doi-asserted-by":"crossref","unstructured":"48) Tada H, Kawashiri MA, Nomura A, Teramoto R, Hosomichi K, Nohara A, Inazu A, Mabuchi H, Tajima A, Yamagishi M. Oligogenic familial hypercholesterolemia, LDL cholesterol, and coronary artery disease. J Clin Lipidol, 2018; 12: 1436-1444","DOI":"10.1016\/j.jacl.2018.08.006"},{"key":"48","doi-asserted-by":"crossref","unstructured":"49) Tada H, Kawashiri MA, Okada H, Teramoto R, Konno T, Yoshimuta T, Sakata K, Nohara A, Inazu A, Kobayashi J, Mabuchi H, Yamagishi M, Hayashi K. Assessment of coronary atherosclerosis in patients with familial hypercholesterolemia by coronary computed tomography angiography. Am J Cardiol, 2015; 115: 724-729","DOI":"10.1016\/j.amjcard.2014.12.034"},{"key":"49","doi-asserted-by":"crossref","unstructured":"50) Tada H, Kawashiri MA, Okada H, Nakahashi T, Sakata K, Nohara A, Inazu A, Mabuchi H, Yamagishi M, Hayashi K. Assessments of Carotid Artery Plaque Burden in Patients With Familial Hypercholesterolemia. Am J Cardiol, 2017; 120: 1955-1960","DOI":"10.1016\/j.amjcard.2017.08.012"},{"key":"50","doi-asserted-by":"crossref","unstructured":"51) Tada H, Kawashiri MA, Nohara A, Inazu A, Mabuchi H, Yamagishi M. Assessment of arterial stiffness in patients with familial hypercholesterolemia. J Clin Lipidol, 2018; 12: 397-402","DOI":"10.1016\/j.jacl.2017.12.002"},{"key":"51","doi-asserted-by":"crossref","unstructured":"52) Tada H, Kawashiri MA, Nohara A, Inazu A, Mabuchi H, Yamagishi M. Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia. Eur Heart J, 2017; 38: 1573-1579","DOI":"10.1093\/eurheartj\/ehx004"},{"key":"52","unstructured":"53) Fahed AC, Wang M, Chaffin M, Bick AG, Patterson C, Natarajan P, Lebo M, Batra P, Ng K, Ellinor PT, Philippakis AA, Kathiresan S, Khera AV. Risk of Myocardial Infarction in Carriers of Familial Hypercholesterolemia Mutations is Modified by Common Variant Genetic Background or Adherence to a Healthy Lifestyle. Circulation, 2019; 140: A15044"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/27\/6\/27_RV17040\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T03:49:26Z","timestamp":1591415366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/27\/6\/27_RV17040\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,1]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.rv17040","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,1]]}}}